NCT03297593 - Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

April 30, 2025

Conditions

Renal Cell Carcinoma

Interventions

DRUG

nivolumab

240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter

DRUG

ipilimumab

After 2 weeks 1mg/kg every 6 weeks

Trial Locations (14)

1011

Centre hospitalier universitaire vaudois - CHUV, Lausanne

1221

Hôpitaux Universitaires de Genève, Geneva

1708

HFR - Hôpital cantonal, Fribourg

3030

Inselspital Bern, Bern

4031

Universitätsspital Basel, Basel

4101

Kantonsspital Baselland Bruderholz, Bruderholz

5001

Kantonsspital Aarau, Aarau

5404

Kantonsspital Baden, Baden

6000

Luzerner Kantonsspital, Lucerne

7000

Kantonsspital Graubünden, Chur

8091

UniversitätsSpital Zürich, Zurich

8401

Kantonsspital Winterthur, Winterthur

8500

Spital Thurgau, Frauenfeld

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER